Primary sclerosing cholangitis secondary prevention: Difference between revisions
| Line 52: | Line 52: | ||
* For [[osteopenia]] and [[osteoporosis]], treat with [[calcium]] 1.0-1.5 g/day and [[vitamin D]] of 1,000 IU/day. | * For [[osteopenia]] and [[osteoporosis]], treat with [[calcium]] 1.0-1.5 g/day and [[vitamin D]] of 1,000 IU/day. | ||
* Add [[bisphosphonates]] in the case of [[osteoporosis]]. | * Add [[bisphosphonates]] in the case of [[osteoporosis]]. | ||
|} | |}<small> | ||
==References== | |||
{{reflist|2}} | {{reflist|2}} | ||
{{WS}} | {{WS}} | ||
{{WH}} | {{WH}}<small> | ||
Latest revision as of 17:27, 6 December 2017
|
Primary sclerosing cholangitis Microchapters |
|
Differentiating Primary sclerosing cholangitis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Primary sclerosing cholangitis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Primary sclerosing cholangitis secondary prevention |
|
Primary sclerosing cholangitis secondary prevention in the news |
|
Blogs on Primary sclerosing cholangitis secondary prevention |
|
Directions to Hospitals Treating Primary sclerosing cholangitis |
|
Risk calculators and risk factors for Primary sclerosing cholangitis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Dima Nimri, M.D. [2]
Overview
Secondary prevention in patients with primary sclerosing cholangitis is aimed at screening for complications and coexisting conditions in these patients. These include screening for complications of liver cirrhosis, screening for colon and gallbladder cancers, as well as metabolic bone disease.
Secondary Prevention
Secondary prevention in patients with primary sclerosing cholangitis is aimed at screening for complications and coexisting conditions in these patients. These include:[1][2][3]
| Complications/ Coexisting Conditions | Presentation | Screening | Management |
|---|---|---|---|
| Liver Cirrhosis |
|
||
| Gallbladder disease |
|
| |
| IBD and associated risk of colon cancer |
|
| |
| Metabolic bone disease |
|
|
References
- ↑ Lazaridis KN, LaRusso NF (2016). "Primary Sclerosing Cholangitis". N. Engl. J. Med. 375 (12): 1161–70. doi:10.1056/NEJMra1506330. PMID 27653566.
- ↑ Chapman R, Fevery J, Kalloo A, Nagorney DM, Boberg KM, Shneider B, Gores GJ (2010). "Diagnosis and management of primary sclerosing cholangitis". Hepatology. 51 (2): 660–78. doi:10.1002/hep.23294. PMID 20101749.
- ↑ Kumar A, Wheatley D, Puttanna A (2016). "Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management". Clin Med Insights Gastroenterol. 9: 25–9. doi:10.4137/CGast.S38451. PMC 4902039. PMID 27330336.